FIGURE 5.

β₂m^−/− mice have type II NKT cells but not type I iNKT cells. A, β₂m^−/− mice have no CD1d-tetramer⁺ type I iNKT cells. β₂m^−/− mice were sensitized and challenged with OVA. Spleen, lung, and BAL fluid (BALF) cells were obtained 24 h after the last OVA challenge and stained with α-GalCer-loaded CD1d tetramers and anti-TCRβ mAb, which are representative of at least three experiments. The number of CD1d-tetramer⁺ type I iNKT cells are shown as a percentage of total lymphocytes. B, β₂m^−/− mice do not respond to intranasal challenge of α-GalCer. Invasive measurement of airway resistance (R_L) was performed 24 h after 2 μg of intranasal challenge of α-GalCer. Data are the mean ± SEM percentage of saline values from two experiments (n = 10–11). C, β₂m^−/− mice do not respond to intranasal challenge of Sphingomonas glycolipid Ag. AHR was measured as in B 24 h after 20 μg of intranasal challenge of Sphingomonas glycolipid Ag. Data are the mean ± SEM percentage of saline values (n = 4–5). D, β₂m^−/− mice have NK1.1⁺ T cells. Spleen, lung, and BAL fluid cells were obtained as in A and stained with anti-NK1.1 mAb and anti-TCRβ mAb. The number of NK1.1⁺ T cells is shown as a percentage of total lymphocytes.